Banco Bilbao Vizcaya Argentaria S.A. Cuts Stake in Pfizer Inc. $PFE

Banco Bilbao Vizcaya Argentaria S.A. cut its holdings in shares of Pfizer Inc. (NYSE:PFE) by 31.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,203,350 shares of the biopharmaceutical company’s stock after selling 564,462 shares during the period. Banco Bilbao Vizcaya Argentaria S.A.’s holdings in Pfizer were worth $29,974,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in PFE. Horizon Financial Services LLC increased its stake in Pfizer by 174.8% during the 4th quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 645 shares in the last quarter. Godfrey Financial Associates Inc. purchased a new stake in shares of Pfizer during the fourth quarter valued at $26,000. YANKCOM Partnership acquired a new position in shares of Pfizer in the 4th quarter valued at $28,000. HFM Investment Advisors LLC raised its stake in Pfizer by 61.0% in the 4th quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 427 shares during the last quarter. Finally, Abound Financial LLC acquired a new stake in Pfizer during the 4th quarter worth about $31,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have weighed in on PFE shares. Argus upgraded Pfizer from a “hold” rating to a “buy” rating and set a $35.00 price target on the stock in a research note on Monday, March 2nd. Bank of America decreased their target price on Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a report on Thursday, April 9th. Wall Street Zen lowered Pfizer from a “buy” rating to a “hold” rating in a research report on Saturday, June 13th. Wolfe Research reiterated an “underperform” rating and issued a $26.00 price target on shares of Pfizer in a report on Thursday, May 14th. Finally, Zacks Research upgraded shares of Pfizer from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 24th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, twelve have issued a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $28.82.

Pfizer Stock Down 0.3%

PFE stock opened at $25.95 on Thursday. Pfizer Inc. has a one year low of $23.11 and a one year high of $28.75. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.94 and a current ratio of 1.25. The firm’s fifty day moving average is $26.30 and its 200 day moving average is $26.34. The firm has a market cap of $147.89 billion, a PE ratio of 19.81 and a beta of 0.34.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.72 by $0.03. The business had revenue of $14.45 billion for the quarter, compared to analyst estimates of $13.84 billion. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The company’s revenue for the quarter was up 5.4% on a year-over-year basis. During the same period in the prior year, the company posted $0.92 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, research analysts forecast that Pfizer Inc. will post 2.99 EPS for the current year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, June 12th. Shareholders of record on Friday, May 8th were given a dividend of $0.43 per share. The ex-dividend date was Friday, May 8th. This represents a $1.72 dividend on an annualized basis and a yield of 6.6%. Pfizer’s dividend payout ratio is currently 131.30%.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.